ST6GALNAC2

Across TCGA pan-cancer cohorts, ST6GALNAC2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ST6GALNAC2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ST6GALNAC2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ST6GALNAC2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC are the cancer types where ST6GALNAC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	1.000	0.669	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

ST6GALNAC2–LSCC (OS)

Open the LSCC breakdown →